Onyx Healthcare Inc. (TPEX:6569)
Taiwan · Delayed Price · Currency is TWD 100.00
-1.50 (-1.48%)
Apr 20, 2026, 1:15 PM CST
Onyx Healthcare Revenue
In the year 2025, Onyx Healthcare had annual revenue of 1.31B TWD with 5.80% growth. Onyx Healthcare had revenue of 315.74M in the quarter ending December 31, 2025, a decrease of -17.47%.
Revenue
1.31B
Revenue Growth
+5.80%
P/S Ratio
3.02
Revenue / Employee
10.94M
Employees
120
Market Cap
3.97B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31B | 72.04M | 5.80% |
| Dec 31, 2024 | 1.24B | -251.61M | -16.85% |
| Dec 31, 2023 | 1.49B | -107.41M | -6.71% |
| Dec 31, 2022 | 1.60B | 398.51M | 33.16% |
| Dec 31, 2021 | 1.20B | -145.54M | -10.80% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 20.51B |
| PharmaEssentia | 15.63B |
| Orient EuroPharma | 4.60B |
| BIONET | 1.24B |
| Sagittarius Life Science | 346.08M |
| Bonraybio | 306.31M |
| BioGend Therapeutics | 222.34M |
| Caliway Biopharmaceuticals | 38.04M |